<DOC>
	<DOC>NCT02164578</DOC>
	<brief_summary>Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients. Especially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.</brief_summary>
	<brief_title>Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>type 2 diabetes duration between 2 and 20 years documented atherosclerotic CVD: major cardiovascular event in medical history or coronary angiography showing a coronary artery stenosis of &gt; 50 % or carotid ultrasound showing an IMT &gt; 1 mm and plaque of carotid artery or left ventricular hypertrophy or macroalbuminuria in the absence of other renal diseases increased hsCRP (&gt; 2 mg/l but &lt; 10 mg/l) and/or increased PAI 1 (&gt; 15 ng/ml) stable treatment with statins (if tolerated) age 40 75 years CV event with need for oral anticoagulation or dual platelet inhibitor therapy or acute coronary syndrome &lt; 12 month before study entry sustained uncontrolled hypertension: systolic bp &gt; 180 mmHg or diastolic bp &gt; 100 mmHg hypersensitivity to the active substance active clinically significant bleeding significant risks for major bleeding concomitant treatment of ACS with antiplatelet therapy in patients with a prior stroke or a transient ischaemic attack (TIA) hepatic disease associated with coagulopathy and clinically relevant bleeding risk chronic renal failure with eGFR &lt; 15 ml/min (MDRD formula) Pregnant or breastfeeding woman and woman without adequate method of contraception.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>